共 50 条
- [41] Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphomaINTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (03) : 396 - 399Makita, ShinichiMaeshima, Akiko MiyagiTaniguchi, HirokazuKitahara, HideakiFukuhara, SuguruMunakata, WataruSuzuki, TatsuyaMaruyama, DaiKobayashi, YukioTobinai, Kensei
- [42] Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximabDRUGS OF TODAY, 2020, 56 (04) : 287 - 294Amaya, M. L.Jimeno, A.Kamdar, M.
- [43] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphomaCANCER SCIENCE, 2021, 112 (07) : 2845 - 2854Terui, YasuhitoRai, ShinyaIzutsu, KojiYamaguchi, MotokoTakizawa, JunKuroda, JunyaIshikawa, TakayukiKato, KojiSuehiro, YoukoFukuhara, NorikoOhmine, KenGoto, HidekiYamamoto, KazuhitoKanemura, NobuhiroUeda, YasunoriIshizawa, KenichiKumagai, KyoyaKawasaki, AtsukoSaito, TomohisaHashizume, MisatoShibayama, Hirohiko
- [44] Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphomaLEUKEMIA RESEARCH, 2014, 38 (08) : 866 - 873Olszewski, Adam J.Winer, Eric S.Castillo, Jorge J.
- [45] A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell LymphomaBLOOD, 2013, 122 (21)Park, Steven I.Richards, Kristy L.Asch, Adam S.Olajide, OludamilolaDeal, Allison M.Ivanova, AnastasiaWall, James G.Sobol, Anna L.Foster, Matthew C.Muss, Hyman B.Shea, Thomas C.
- [46] Efficacy and Safety of Reduced-Dose Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone ( Pola-R-CHP) in Patients over 80 with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)BLOOD, 2023, 142Miyao, KotaroWakayama, TomoyoshiOzaki, SomiNumata, MasayaNegishi, ShutoOhara, FumiyaMotegi, KentaWakabayashi, HiroyaSawa, HitomiSakai, ToshiyasuInagaki, YuichiroSawa, Masashi
- [47] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-EscalationBLOOD, 2015, 126 (23)Bartlett, Nancy L.Chen, Andy I.Kolibaba, Kathryn S.Lamy, ThierryJones, SuraiHirata, JamieSharman, Jeff P.
- [48] Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistryLEUKEMIA & LYMPHOMA, 2017, 58 (07) : 1607 - 1616Bartlett, Nancy L.Smith, Mitchell R.Siddiqi, TanyaAdvani, Ranjana H.O'Connor, Owen A.Sharman, Jeff P.Feldman, TatyanaSavage, Kerry J.Shustov, Andrei R.Diefenbach, Catherine S.Oki, YasuhiroPalanca-Wessels, Maria CorinnaUttarwar, MayurLi, MarthaYang, JingJacobsen, Eric D.
- [49] A PROGNOSTIC SCORE FOR SURVIVAL IN PATIENTS OLDER THAN 65 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMAREVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2018, 70 (01): : 46 - 52Candelaria, MyrnaReynoso-Noveron, NancyPonce, MayraCastillo-Llanos, RodrigoNolasco-Medina, DianaCantu-de-Leon, David
- [50] Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell LymphomaBLOOD, 2021, 138Steiner, Raphael E.Strati, PaoloFlowers, Christopher R.Neelapu, Sattva S.Green, Michael R.Nastoupil, LorettaHagemeister, Fredrick B.Feng, LeiAhmed, SairahNair, RanjitFayad, LuisLee, Hun JuRodriguez, Maria AlmaWestin, Jason R.